$720 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 75 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VINC | Exit | VINCERX PHARMA INC | $0 | – | -70,467 | -100.0% | -0.01% | – |
| GNRC | Exit | GENERAC HLDGS INC | $0 | – | -2,310 | -100.0% | -0.05% | – |
| KNTE | Exit | KINNATE BIOPHARMA INC | $0 | – | -91,673 | -100.0% | -0.12% | – |
| AMD | Exit | ADVANCED MICRO DEVICES INC | $0 | – | -15,773 | -100.0% | -0.13% | – |
| VTGN | Exit | VISTAGEN THERAPEUTICS INCcall | $0 | – | -1,500,000 | -100.0% | -0.14% | – |
| ISEE | Exit | IVERIC BIO INCcall | $0 | – | -200,000 | -100.0% | -0.21% | – |
| QQQ | Exit | INVESCO QQQ TRunit ser 1 | $0 | – | -8,186 | -100.0% | -0.24% | – |
| ABNB | Exit | AIRBNB INC | $0 | – | -27,700 | -100.0% | -0.26% | – |
| V | Exit | VISA INC | $0 | – | -12,600 | -100.0% | -0.26% | – |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -3,291,135 | -100.0% | -0.31% | – |
| CCCC | Exit | C4 THERAPEUTICS INC | $0 | – | -705,736 | -100.0% | -0.57% | – |
| FB | Exit | META PLATFORMS INCcl a | $0 | – | -50,000 | -100.0% | -0.86% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -753,037 | -100.0% | -0.86% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INCcall | $0 | – | -75,000 | -100.0% | -1.17% | – |
| FIVN | Exit | FIVE9 INC | $0 | – | -140,968 | -100.0% | -1.37% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -200,000 | -100.0% | -1.59% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -3,381,600 | -100.0% | -2.72% | – |
| XBI | Exit | SPDR SER TRs&p biotech | $0 | – | -437,748 | -100.0% | -3.48% | – |
| SPY | Exit | SPDR S&P 500 ETF TRcall | $0 | – | -199,500 | -100.0% | -8.05% | – |
| QQQ | Exit | INVESCO QQQ TRcall | $0 | – | -992,800 | -100.0% | -29.76% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.